EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Successful Therapy over 12 Months of People with Cystic Fibrosis with Rare Non-phe508del Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutations with Elexacaftor/Tezacaftor/Ivacaftor (ETI)

Tomke Sütering, Sebastian F N Bode iD, Rainald Fischer, Dorit Fabricius iD

Advances in Respiratory Medicine · 2024

DOI: 10.3390/arm92060049 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Advances in Respiratory Medicine, 2024. Verfasst von Tomke Sütering und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm University, 89075 Ulm, Germany. Hauptthemen laut MEDLINE: Cystic Fibrosis, Benzodioxoles, Cystic Fibrosis Transmembrane Conductance Regulator, Indoles. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Elexacaftor/Tezacaftor/Ivacaftor (ETI) is a CFTR modulator therapy approved for people with cystic fibrosis (pwCF) who have at least one phe508del mutation. However, its approval in the European Union (EU) for pwCF with non-phe508del mutations is lacking, because data on treatment response in this subgroup are scarce.

Methods

This retrospective observational study evaluated six pwCF (ages 6 to 66) with responsive CFTR mutations (M1101K, R347P, 2789+5G>A, G551D) undergoing off-label ETI therapy. Evaluations were conducted at 0, 3, 6, 9, and 12 months, assessing lung function (FEV1), sweat chloride levels, body mass index (BMI), quality of life, medication satisfaction, ear, nose and throat (ENT) symptoms, and physical activity. A control group of four pwCF with classic symptoms and no ETI treatment was included.

Results

FEV1 improved significantly after 3 and 6 months (p < 0.05) and stabilized by 12 months. Sweat chloride levels decreased significantly, with four pwCF achieving levels

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisBenzodioxolesCystic Fibrosis Transmembrane Conductance RegulatorIndolesQuinolonesAminophenolsHumansRetrospective StudiesFemaleMaleMutationPyrazolesDrug CombinationsAdultAdolescentPyrrolesChildPyridinesMiddle AgedYoung AdultTreatment OutcomePyrrolidines

Stichwörter der Autor:innen

cystic fibrosiselexacaftor/tezacaftor/ivacaftornon-phe508del CFTR mutationsoff-label userare CFTR mutations

Substanzen

BenzodioxolesCystic Fibrosis Transmembrane Conductance RegulatorIndolesQuinolonesAminophenolsPyrazolesDrug CombinationselexacaftorPyrrolestezacaftor

Autor:innen und Institutionen

  • Department of Pediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm University, 89075 Ulm, Germany.
  • Cystic Fibrosis Center Munich West, Ludwig Maximilian University (LMU), 81241 Munich, Germany.

ORCID-Profile: Sebastian F N Bode, Dorit Fabricius

Zitieren

APA

Sütering, T., Bode, S. F. N., Fischer, R., & Fabricius, D. (2024). Successful Therapy over 12 Months of People with Cystic Fibrosis with Rare Non-phe508del Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutations with Elexacaftor/Tezacaftor/Ivacaftor (ETI). Advances in Respiratory Medicine. https://doi.org/10.3390/arm92060049

Vancouver

Sütering T, Bode SFN, Fischer R, Fabricius D. Successful Therapy over 12 Months of People with Cystic Fibrosis with Rare Non-phe508del Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutations with Elexacaftor/Tezacaftor/Ivacaftor (ETI). Advances in Respiratory Medicine. 2024. doi:10.3390/arm92060049

BibTeX
@article{Stering2024,
  author = {Sütering, Tomke and Bode, Sebastian F N and Fischer, Rainald and Fabricius, Dorit},
  title = {Successful Therapy over 12 Months of People with Cystic Fibrosis with Rare Non-phe508del Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutations with Elexacaftor/Tezacaftor/Ivacaftor (ETI)},
  journal = {Advances in Respiratory Medicine},
  year = {2024},
  doi = {10.3390/arm92060049}
}
Kostenlos starten →